β¨ Medicine Distribution Consents
29 MAY 2008 NEW ZEALAND GAZETTE, No. 89
2429
Product:
Active Ingredient:
Carvelol
Carvedilol 3.125mg
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Pacific Pharmaceuticals Limited (part of Mylan)
Manufacturer:
Specifar SA, Aigaleo, Athens, Greece
Product:
Active Ingredient:
Carvelol
Carvedilol 6.25mg
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Pacific Pharmaceuticals Limited (part of Mylan)
Manufacturer:
Specifar SA, Aigaleo, Athens, Greece
Product:
Active Ingredients:
Fosamax Plus
Alendronate sodium trihydrate 91.37mg equivalent to 70mg alendronic acid
Colecalciferol 140Β΅g equivalent to 5600 IU
Dosage Form:
Tablet
New Zealand Sponsor:
Merck Sharp & Dohme (New Zealand) Limited
Manufacturer:
MSD Frosst Iberica SA, Alcala de Henares, Madrid, Spain
Product:
Active Ingredient:
Invega
Paliperidone 12mg
Dosage Form:
Modified release tablet
New Zealand Sponsor:
Johnson & Johnson (New Zealand) Limited
Manufacturer:
Alza Corporation, Vacaville, California, United States of America
Product:
Active Ingredient:
Invega
Paliperidone 3mg
Dosage Form:
Modified release tablet
New Zealand Sponsor:
Johnson & Johnson (New Zealand) Limited
Manufacturer:
Alza Corporation, Vacaville, California, United States of America
Product:
Active Ingredient:
Invega
Paliperidone 6mg
Dosage Form:
Modified release tablet
New Zealand Sponsor:
Johnson & Johnson (New Zealand) Limited
Manufacturer:
Alza Corporation, Vacaville, California, United States of America
Product:
Active Ingredient:
Invega
Paliperidone 9mg
Dosage Form:
Modified release tablet
New Zealand Sponsor:
Johnson & Johnson (New Zealand) Limited
Manufacturer:
Alza Corporation, Vacaville, California, United States of America
Product:
Active Ingredient:
Lantus OptiSet
Insulin glargine 3.6378mg/mL
Dosage Form:
Solution for injection
New Zealand Sponsor:
sanofi-aventis new zealand limited
Manufacturer:
Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany
Dated this 27th day of May 2008.
ANTHONY HILL, Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation given by the Minister of Health on 6 July 2001).
go3803
Renewal of Provisional Consent to the Distribution of a Medicine
Pursuant to section 23(4A) of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product:
Active Ingredient:
Viramune
Nevirapine hemihydrate 10.35mg/mL equivalent to 10mg/mL nevirapine
Dosage Form:
Oral suspension
New Zealand Sponsor:
Boehringer Ingelheim (NZ) Limited
Manufacturer:
Boehringer Ingelheim Roxane Inc, Columbus, Ohio, United States of America
Note: This consent is valid for two years from the date of publication of this notice.
Dated this 27th day of May 2008.
ANTHONY HILL, Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation given by the Minister of Health on 6 July 2001).
go3804
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2008, No 89
Gazette.govt.nz —
NZ Gazette 2008, No 89
β¨ LLM interpretation of page content
π₯ Consent to the Distribution of New Medicines
π₯ Health & Social Welfare27 May 2008
Medicines, Distribution, Consent, Carvelol, Fosamax Plus, Invega, Lantus OptiSet
- ANTHONY HILL, Deputy Director-General, Sector Accountability and Funding Directorate
π₯ Renewal of Provisional Consent to the Distribution of a Medicine
π₯ Health & Social Welfare27 May 2008
Medicines, Distribution, Provisional Consent, Renewal, Viramune
- ANTHONY HILL, Deputy Director-General, Sector Accountability and Funding Directorate